Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
In this Review, Golebiewska and colleagues summarize the main features of the immunosuppressive microenvironment in glioblastoma (GBM) and discuss how different therapeutic approaches reshape GBM immunity.
Ubellacker and Dixon summarize the latest discoveries on ferroptosis in cancer, covering the molecular and cellular pathways underlying sensitivity and resistance to this type of cell death, as well as potential translational applications in cancer therapeutics.
Kim and colleagues provide an overview of the current state of the art of nanomaterials and their application in immuno-oncology, discussing preclinical development and the clinical landscape.
Dotti and colleagues review chimeric antigen receptor (CAR)-engineered cell-based cancer therapy and overview its transition for solid tumors from CAR T to CAR-engineered innate immune cells, discussing strengths and limitations for clinical application.
Trowbridge and colleagues provide a comprehensive review of clonal hematopoiesis in diverse cancer settings, from myeloid malignancies to solid tumors, covering underlying molecular and cellular mechanisms and exploring therapy-related approaches.
Thomas and colleagues review the latest preclinical and clinical studies on small-cell lung cancer and outline future directions on therapeutic strategies highlighting a role for reverse translation in the treatment of this disease.
Boussiotis and colleagues provide an overview of the features of the tumor microenvironment, with emphasis on myeloid cells and non-immune cells such as fibroblasts and endothelial cells, and their role in response to immune checkpoint blockade.
Masri and colleagues review the latest studies on the influence of circadian rhythms in cancer biology, discussing possible connections between chronobiology and cancer prevention and treatment.
Haake and colleagues provide an overview of recent research on biomarkers to predict immunotherapy response in clear cell renal cell carcinoma and discuss the predictive and prognostic biomarkers to prioritize in this context.
Ruppin and colleagues overview recent research on the use of AI frameworks in precision oncology, describe ten hallmarks of their contributions across cancer detection, therapy optimization and treatment discovery, and discuss key challenges in clinical implementation
McGaha and colleagues review recent research on the metabolic programs of tumor-associated macrophages across cancer types and discuss their implications on potential therapeutic vulnerabilities.
Asciolla, Wu et al. review advances in CDK4 and CDK6 targeting and current challenges and opportunities, highlighting novel strategies to overcome treatment resistance and the role of the immune system in therapy response.
Kaplan and colleagues discuss adaptations in the bone environment in the context of cancer, reflect on advanced technologies to study these bone niches and summarize how a remodeled bone marrow milieu can prime other sites for metastasis.
Fong and colleagues provide a Review on γδ T cells as mediators of anti-tumor immunity, discuss their role in the tumor microenvironment and reflect on therapeutic approaches to exploit γδ T cells.
Rebecca and colleagues discuss the complex biology of metastatic melanoma, as well as determinants of resistance to therapy and existing and promising therapy strategies.
Prives and colleagues comprehensively discuss the current knowledge on cancer-related mutations of p53 and the impact they have on anticancer immunity.
Stegmaier and colleagues provide a review on the latest development in targeting the cancer epigenome, give an overview of distinct drug classes, and discuss therapeutic possibilities and challenges.
Vousden and colleagues discuss the multifactorial role of mitochondrial folate metabolism in cancer and metastasis and reflect on potential therapeutic opportunities.
